Fluticasone furoate + vilanterol	Moxifloxacin	Adverse effects 	36157	36262	and similar incidences observed in the FF/VI 200/25 μg and moxifloxacin groups (40 and 41%, respectively)
Fluticasone furoate + vilanterol	Control	Adverse effects 	-1	-1	<td align="left" colspan="1" rowspan="1"><bold> Adverse events/serious adverse events</bold></td><td align="center" colspan="1" rowspan="1">0</td><td align="center" colspan="1" rowspan="1">0</td>
Fluticasone furoate + vilanterol	Control	Adverse effects 	38953	39065	Single doses of FF 4000 μg were also well tolerated, with no serious adverse events or significant AEs observed.
Moxifloxacin	Control	QTc (individual correction) time	27959	28056	Single-dose moxifloxacin (400 mg) produced an increase in time-matched QTci compared with placebo
Fluticasone furoate + vilanterol	Control	Adverse effects 	35841	35966	There were no serious adverse events or subject withdrawals due to AEs. No AEs were severe and all resolved during the study.
